Search

Displaying results 8011 - 8020 of 10000 in total
  1. Drug

    MEDI-6469

    go.drugbank.com/drugs/DB15306
    Investigational

    MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

  2. Drug

    Drostanolone

    go.drugbank.com/drugs/DB00858
    ExperimentalIllicit

    Drostanolone is indicated in postmenopausal women with recurrent breast cancer, in a combined hormone therapy.

  3. Drug

    Gam-COVID-Vac

    go.drugbank.com/drugs/DB15848
    Investigational

    June 2020, and were completed in early August 2020. … Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia.

  4. Drug

    Zavacorilant

    go.drugbank.com/drugs/DB21509
    Investigational

    Zavacorilant is under investigation in clinical trial NCT04672512 (Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants). … The usage of the INN stem '-corilant' in the name indicates that Zavacorilant is a glucocorticoid receptor antagonist (non-steroidal).

  5. Drug

    Leukotriene C4

    go.drugbank.com/drugs/DB08855
    Experimental

    It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. … It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some vascular smooth muscle. (From Dictionary of Prostaglandins and Related Compounds, 1990)

    Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine
  6. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor). Xiliertinib has a monoisotopic molecular weight of 442.21 Da. … The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  7. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors). … The usage of the INN stem '-trectinib' in the name indicates that Paltimatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.

  8. Drug

    D-fluoromethyltyrosine F-18

    go.drugbank.com/drugs/DB15296
    Investigational

    D-fluoromethyltyrosine F-18 is under investigation in clinical trial NCT01089998 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety … , Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations).

  9. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With … Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).

  10. Drug

    Inakalant

    go.drugbank.com/drugs/DB20424
    Investigational

    Inakalant is under investigation in clinical trial NCT00255281 (Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation). Inakalant has a monoisotopic molecular weight of 446.25 Da. … The usage of the INN stem '-kalant' in the name indicates that Inakalant is a potassium channel blocker.